Navigation Links
Viral Genetics Updates HIV/AIDS and Drug Resistant Cancer Research Programs
Date:6/14/2011

nded protocol is now being finalized by the investigators, and may be modified again in the future although we do not anticipate any significant additional delays.

While the central aim of the study is to determine efficacy of our MDT compounds in certain patients in certain cancers, and we are involved in reviewing the study's design, the study itself is being conducted and controlled by the hospital investigators. IRB review is expected to be completed between June and July 2011 and the Company expects the I-IND to be submitted shortly thereafter.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate,
'/>"/>

SOURCE Viral Genetics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
10. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
11. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli Lilly ... of its long-standing technology transfer program to increase the ... in 2003, the effort included Lilly donating manufacturing technology ... China , India ... South Africa – all MDR-TB ,hot spots., ...
(Date:10/27/2014)... 27, 2014 Research and Markets has ... 2014-2018" report to their offering. H1N1 ... a variant of the swine H1N1 virus, known as H1N1v ... nose, throat, and lungs. H1N1 virus is an RNA virus ... animal species such as humans, swine, birds, seals, and horses. ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... Bulletin Board: GOVX ) announced today the publication ... its HIV/AIDS vaccine products. The article, titled "Phase 1 Safety ... Vaccines Expressing HIV-1 Virus-like Particles," will appear in the March ... Diseases . A PDF of the article is available at ...
... Inc., a leader in room temperature biostability technology, ... (IQT). IQT is the independent, strategic investment firm ... mission of the U.S. Intelligence Community. ... pioneered recent innovations in ambient storage of biological ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
(Date:10/30/2014)... at least 2 years old to be covered by ... guidance exists other than the general recommendation by national ... least the first six months. , So what ... that motivated researchers at the University at Buffalo School ... patterns of American infants at 6 months and 12 ...
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, ... showing that you are never too young to give ... Tracey and Carl at the 2013 Santa Arriving By ... Beach Chamber of Commerce. Tracey gave Timothy a special ... wear his real fireman’s hat, and extending an offer ...
(Date:10/30/2014)... Five months after their expansion, the ... new branding and a website to accompany their recent ... Mepham’s promotion to name partner earlier this year, Hodgkinson ... Mepham’s name and better reflect their combined litigation expertise. ... decision to implement new branding reflects Hodgkinson Street Mepham’s ...
(Date:10/30/2014)... Reinberg HealthDay Reporter , WEDNESDAY, ... men with prostate cancer who also have certain heart problems ... a new study suggests. , , The therapy in question is ... to reduce levels of male hormones to prevent the growth ... current research, this hormone therapy was linked to triple the ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Hodgkinson Street Mepham Rebrands 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) a ... for the second quarter ended June 30, 2009. The company ... in prescription sales and pharmacy transfers. Gross margins increased 7.8% ... $396,271. , , "Consumers are increasingly switching ...
... FT. WASHINGTON, Pa., Aug. 25 The makers of ZYRTEC(R) ... announced the availability of two new allergy solutions to help ... Children,s ZYRTEC(R) PERFECT MEASURE(R) and ZYRTEC(R) Itchy Eye Drops are ... products. The company also announced the launch of AllergyCast, ...
... , CHICAGO, Aug. 25 Health care costs are ... according to Aon Consulting, the global human capital consulting organization of ... (NYSE: AOC ). , , ... more than 60 leading health care insurers, representing more than 100 million ...
... food has been detected in unusually high levels in ... condition pre-eclampsia. These results are important because they ... pre-eclampsia and may help scientists to understand the cause ... at the University of Leeds took blood samples from ...
... polyps, sessile serrated polyps (also called sessile serrated adenomas), ... polyps share molecular features with a subgroup of colon ... be precursors of cancer through a hyperplastic polyp to ... arise in the proximal colon. Sessile serrated polyps may ...
... that connective tissue growth factor (CCN2) plays a ... systems. Fibrosis is a scarring condition that is ... cell function and can cause organ dysfunction and ... liver is the activation of hepatic stellate cells ...
Cached Medicine News:Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 2Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 4Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 2Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 3Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 4Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 5Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 6Health News:New link between pre-eclampsia and diet 2Health News:Reinterpretation of proximal colon polyps called hyperplastic in 2001 2
Span Diagnostics Limited...
Malaria (P. fal.) Ag Rapid Test...
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
... The NOW® Malaria Test is a field or ... Malaria infection. It is intended for the detection ... and an antigen that is common to all ... (P.f.), Plasmodium vivax (P.v.), Plasmodium ...
Medicine Products: